United TherapeuticsUTHR -1.18%88 PB Ratio is 3.88 as of Jun. 25, 2026, which is 75% above its 10-year median of 2.22. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.36 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, United Therapeutics ranks worse than 77.01% on this metric.
United Therapeutics Corp stock PB Ratio (=3.93) is close to 10-year high of 4.2.
The historical rank and industry rank for United Therapeutics's PB Ratio or its related term are showing as below:
UTHR'
s PB Ratio Range Over the Past 10 Years
Min: 1.28 Med: 2.22 Max: 4.2
Current: 3.88
During the past 13 years, United Therapeutics's highest PB Ratio was 4.20. The lowest was 1.28. And the median was 2.22.
UTHR's PB Ratio is ranked worse than 77.01% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs UTHR: 3.88
During the past 12 months, United Therapeutics's average Book Value Per Share Growth Rate was -7.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 16.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of United Therapeutics was 106.90% per year. The lowest was -11.80% per year. And the median was 17.90% per year.
Back to Basics: PB Ratio
United Therapeutics (NAS:UTHR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
United Therapeutics PB Ratio Related Terms
United Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for United Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where United Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
United Therapeutics (UTHR) has a PB Ratio of 3.88 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on United Therapeutics and its competitors. This is 75% above median its historical median of 2.22. Over the past decade, United Therapeutics' PB Ratio has ranged from 1.28 to 4.20. According to the industry distribution chart, United Therapeutics ranks #710 out of 922 companies in the Drug Manufacturers industry, placing it in the top 77%.
Is United Therapeutics' PB Ratio too high?
United Therapeutics' current PB Ratio of 3.88 is 75% above median its 10-year median of 2.22. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 4.20. The Drug Manufacturers industry median PB Ratio is 1.86. United Therapeutics' value of 3.88 is 109.2% above this industry median. Based on the distribution chart, United Therapeutics ranks #710 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' PB Ratio compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #710 out of 922 companies for PB Ratio. This places United Therapeutics in the lower half of its industry. The industry median PB Ratio is 1.86. United Therapeutics' value of 3.88 is 109.2% above this benchmark. Historically, United Therapeutics' own PB Ratio has ranged from 1.28 to 4.20 over the past decade. While the company's 10-year median is 2.22 vs. the industry median of 1.86, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current PB Ratio of 3.88 is 109.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current PB Ratio is 3.88, which is 75% above median its own 10-year median of 2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.36, compared to a current price of $543.39 — trading 40.6% above its estimated fair value. The current PB Ratio is 3.88, which is 75% above median its 10-year median of 2.22 and 109.2% above the Drug Manufacturers industry median of 1.86. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For United Therapeutics (UTHR), the current PB Ratio is 3.88 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $543.39 is trading 40.6% above its estimated GF Value™ of $386.36.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
PB Ratio: 3.88 (75% above median its 10-year median of 2.22)
GF Value™: $386.36 vs. price of $543.39 (40.6% above fair value)
Industry Position: 109.2% above the Drug Manufacturers median (#710 of 922)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
